By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. (0R1D.L)

LSE Currency in USD
$0.49
-$0.01
-1.48%
Last Update: 17 Jul 2025, 05:00
$115.46M
Market Cap
-1.23
P/E Ratio (TTM)
Forward Dividend Yield
$0.29 - $2.11
52 Week Range

0R1D.L Stock Price Chart

Explore Sangamo Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0R1D.L price movements and trends.

There is nothing to show.

0R1D.L Company Profile

Discover essential business fundamentals and corporate details for Sangamo Therapeutics, Inc. (0R1D.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

IPO Date

7 Nov 2014

Employees

183.00

CEO

Alexander D. Macrae Ch.B, M.B., MRCP,

Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

0R1D.L Financial Timeline

Browse a chronological timeline of Sangamo Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 11 May 2026

Upcoming earnings on 16 Mar 2026

Upcoming earnings on 10 Nov 2025

Upcoming earnings on 4 Aug 2025

Revenue estimate is $29.90M.

Earnings released on 12 May 2025

EPS came in at -$0.14 falling short of the estimated -$0.12 by -19.36%, while revenue for the quarter reached $6.44M, missing expectations by -13.21%.

Earnings released on 17 Mar 2025

EPS came in at -$0.11 falling short of the estimated -$0.09 by -21.98%, while revenue for the quarter reached $7.55M, missing expectations by -75.38%.

Earnings released on 13 Nov 2024

EPS came in at $0.04 surpassing the estimated -$0.02 by +362.30%, while revenue for the quarter reached $49.40M, beating expectations by +378.84%.

Earnings released on 7 Aug 2024

EPS came in at -$0.18 falling short of the estimated -$0.15 by -20.73%, while revenue for the quarter reached $356.00K, missing expectations by -94.83%.

Earnings released on 10 May 2024

EPS came in at -$0.27 falling short of the estimated -$0.21 by -27.35%, while revenue for the quarter reached $481.00K, missing expectations by -92.43%.

Earnings released on 13 Mar 2024

EPS came in at -$0.34 falling short of the estimated -$0.26 by -32.43%, while revenue for the quarter reached $2.04M, missing expectations by -74.81%.

Earnings released on 2 Nov 2023

EPS came in at -$0.59 falling short of the estimated -$0.32 by -84.38%, while revenue for the quarter reached $9.40M, beating expectations by +0.41%.

Earnings released on 9 Aug 2023

EPS came in at -$0.66 falling short of the estimated -$0.34 by -95.28%, while revenue for the quarter reached $6.84M, missing expectations by -59.19%.

Earnings released on 27 Apr 2023

EPS came in at $0.12 surpassing the estimated -$0.33 by +138.06%, while revenue for the quarter reached $157.96M, beating expectations by +556.38%.

Earnings released on 23 Feb 2023

EPS came in at -$0.32 surpassing the estimated -$0.36 by +12.35%, while revenue for the quarter reached $27.23M, beating expectations by +1.39%.

Earnings released on 2 Nov 2022

EPS came in at -$0.34 surpassing the estimated -$0.36 by +5.38%, while revenue for the quarter reached $26.46M, missing expectations by -0.48%.

Earnings released on 3 Aug 2022

EPS came in at -$0.29 surpassing the estimated -$0.35 by +17.39%, while revenue for the quarter reached $29.38M, beating expectations by +19.28%.

Earnings released on 2 May 2022

EPS came in at -$0.30 surpassing the estimated -$0.31 by +3.34%, while revenue for the quarter reached $28.23M, beating expectations by +3.46%.

Earnings released on 22 Feb 2022

EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.52%, while revenue for the quarter reached $27.99M, beating expectations by +4.34%.

Earnings released on 4 Nov 2021

EPS came in at -$0.33, while revenue for the quarter reached $27.87M.

Earnings released on 30 Sept 2021

EPS came in at -$0.33, while revenue for the quarter reached $28.56M.

Earnings released on 31 Mar 2021

EPS came in at -$0.32, while revenue for the quarter reached $26.28M.

Earnings released on 31 Dec 2020

EPS came in at -$0.29, while revenue for the quarter reached $25.80M.

Earnings released on 30 Sept 2020

EPS came in at -$0.01, while revenue for the quarter reached $57.76M.

0R1D.L Stock Performance

Access detailed 0R1D.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
0R1D.L
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
0R1D.L
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More